Author: Xie, Xiangyang; Jiang, Yuanliang; Zeng, Yuan; Liu, Hui
Title: Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-alpha1b for COVID-19 Cord-id: sb67s2z2 Document date: 2020_1_1
ID: sb67s2z2
Snippet: Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity The globally pandemic outbreak suggests that COVID-19 was highly infectious and difficult to control A dual-combination of ribavirin and interferon-alpha has been the widely used regimen for the treatment of this disease in China However, due to the
Document: Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity The globally pandemic outbreak suggests that COVID-19 was highly infectious and difficult to control A dual-combination of ribavirin and interferon-alpha has been the widely used regimen for the treatment of this disease in China However, due to the varying results of treatment with these drugs, a novel antiviral combination therapy is urgently needed This case reports the usage of lopinavir/ritonavir-based combination antiviral regimen for a patient with SARS-CoV-2 infection
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date